Prof Jeanne Tie
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
352 Scholarly works
1 Projects
HIGHLIGHTS
2026
Journal article
A Phase 1 Study of PF-07062119, an Anti-GUCY2C/Anti-CD3 Bispecific Fc Antibody, in Patients With Advanced Gastrointestinal Cancers.
DOI: 10.1158/2767-9764.CRC-26-01012026
Journal article
Reproducibility of overall survival in metastatic colorectal cancer randomized trials using ARCAD-Derived external control arms.
DOI: 10.1093/jnci/djag2912026
Journal article
Highly Accurate Detection of Circulating Tumor DNA for Monitoring Minimal Residual Disease in Solid Tumors: Analytical and Clinical Validation of the Haystack MRD Assay.
DOI: 10.1016/j.jmoldx.2026.07.0062026
Journal article
Liquid Biopsy in Biliary Tract Cancer: When Tissue is Not Enough.
DOI: 10.1158/1078-0432.CCR-26-20902026
Journal article
Early-Onset Colorectal Cancer With Liver-Only Metastases: A Retrospective Cohort Study Integrating Prospectively Collected Real-World Clinical and Molecular Data From an Australian National Database (2009–2024) to Guide Treatment Planning
DOI: 10.5694/mja2.702662026
Journal article
Artificial Intelligence-Assisted Risk Stratification in Stage II Colorectal Cancer: Multi-Institutional Validation of Semantically Enhanced Deep Learning.
DOI: 10.1053/j.gastro.2026.07.0092026
Research grants (ARC, NHMRC, MRFF)
Advancing Precision Medicine for Colorectal Cancer Through Liquid Biopsy
RECENT SCHOLARLY WORKS
2026
Journal article
7RO Molecular correlates of enhanced outcome with first-line (1L) encorafenib cetuximab (EC) ± mFOLFOX6 in BRAF V600E-mutant metastatic colorectal cancer (mCRC) from the BREAKWATER study
DOI: 10.1016/j.annonc.2026.05.0112026
Journal article
114P Phase I/Ib study of divarasib (DIVA) cetuximab (CETUX) ± FOLFOX for KRAS G12C-mutated (mut) metastatic colorectal cancer (mCRC)
DOI: 10.1016/j.annonc.2026.05.1152026
Journal article
Diagnostic and predictive utility of peritoneal tumor DNA in gastroesophageal cancer: A prospective multicenter study.
DOI: 10.1200/jco.2026.44.16_suppl.41012026
Journal article
The CO.33/BATTMAN trial: A phase 3 randomized study of botensilimab balstilimab versus best supportive care in chemorefractory unresectable colorectal adenocarcinoma that is not dMMR/MSI-H.
DOI: 10.1200/JCO.2026.44.16_suppl.TPS3676